Related Experiment Video
Updated: Aug 16, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
New biological agents in the treatment of advanced non-small cell lung cancer
Phuong Khanh H Morrow1, Edward S Kim
1Departments of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4095, USA.
Abstract:
Molecularly targeted therapies that are more tumor specific in their efficacy, with associated fewer toxicities, are currently being developed. Specific biomarkers that may predict response or resistance to a particular agent are being sought. Several classes of compounds now target specific steps in cellular proliferation and apoptosis. These include epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial cell targeting agents, matrix metalloproteinase inhibitors, farnesyltransferase inhibitors, retinoids, proteosome inhibitors, and raf/MAPkinase (mitogen-activated protein kinase) inhibitors. Many of these agents, such as bortezomib, have demonstrated promise in the fields of non-small cell lung cancer (NSCLC). However, a cautionary perspective must be maintained because agents such as bexarotene, which showed promise in early studies, have proved disappointing in randomized trials. As the number of therapeutic agents increases in NSCLC, there will be greater emphasis on the selection of an appropriate patient population in which to give specific, targeted therapies.
Insights
New molecularly targeted therapies aim for greater tumor specificity and fewer toxicities in non-small cell lung cancer (NSCLC) treatment. Identifying predictive biomarkers is crucial for selecting patients for these advanced, targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Development of molecularly targeted therapies is advancing for improved tumor specificity and reduced toxicity.
- Identification of predictive biomarkers for treatment response and resistance is a key research area.
- Targeted agents disrupt specific cellular processes like proliferation and apoptosis.
Purpose of the Study:
- To review current molecularly targeted therapies for non-small cell lung cancer (NSCLC).
- To discuss the role of biomarkers in patient selection for targeted treatments.
- To highlight the evolving landscape of precision medicine in NSCLC.
Main Methods:
- Review of existing literature on targeted therapies in NSCLC.
- Categorization of targeted agents based on their molecular targets (e.g., EGFR inhibitors, proteasome inhibitors).
- Discussion of clinical trial outcomes and the importance of patient stratification.
Main Results:
- Several classes of targeted agents show promise in NSCLC, including EGFR inhibitors and proteasome inhibitors.
- Early promising results for some agents (e.g., bexarotene) have not translated into randomized trial success.
- Bortezomib demonstrates potential in NSCLC treatment.
Conclusions:
- The increasing number of targeted agents necessitates careful patient selection for optimal efficacy in NSCLC.
- Biomarker discovery is essential for personalized medicine approaches in NSCLC.
- A balanced perspective is required, acknowledging both the promise and limitations of targeted therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...